NR 526 Week 5 Case Study Assignment: Hepatitis C
Chamberlain University
Advanced Pathophysiology, Health Assessment, and Pharmacology for Nurse
... [Show More] Educators
NR 526 Week 5 Case Study Assignment: Hepatitis C
NR 526 Week 5 Case Study Assignment: Hepatitis C
Chamberlain University
Advanced Pathophysiology, Health Assessment, and Pharmacology for Nurse Educators
Hepatitis C Case Study
The purpose of this assignment is to design a scenario that can be used in a simulation lab to teach and train nursing students how to assess for Hepatitis C. This scenario will also help the student to review patient records to ensure that the patient has had the appropriate laboratory tests performed, as well as, determine if the patient is receiving the appropriate treatment. The following objectives must be met by the students to successfully pass the simulation lab scenario.
1) At the end of this simulation, the learner will be able to demonstrate their learning of the signs and symptoms of Hepatitic C by discussion.
2) By the end of this simulation the learner will be able to identify and discuss the modifiable and non-modifiable risk factors of Hepatitis C.
3) At the end of this simulation, the learner will be able to select and assess lab tests and values to determine if a patient is positive for Hepatitis C.
4) The learner will also be able to assess the patient medications to determine if the patient is on the correct regimen by the end of this simulation.
5) At the end of the simulation, the learner will be able to discuss the treatments that are available to patients with Hepatitis C.
Hepatitis C (HCV) is a viral infection that causes inflammation and damage to the liver. Approximately 30,000 people in the United States were diagnosed with HCV in 2014. People at risk for HCV include those that are intravenous drug users, past or present, individuals who received blood products or had an organ transplant before 1992, hemodialysis patients who have been on dialysis for many years, healthcare workers who have received a needle stick from a patient infected with HCV, HIV patients, or people born to mothers infected with HCV (Centers for Disease Control and Prevention, n.d.). Among these, modifiable risk factors include ceasing the use of intravenous drugs, not having unprotected sex with individuals infected with HIV, and proper use of personal protective equipment if working in the healthcare field. Non-modifiable risk factors include receiving blood products or an organ transplant before 1992, many years of dialysis, HIV infection, and being born to a mother infected with HCV.
One function of the liver is to filter the blood in the human body to remove things such as bacteria and foreign particles. HCV causes damage to the liver by causing necrosis and scarring to the liver by damaging and obstructing bile canaliculi in the liver (McCance & Huether, 2014). This can be detrimental to the function of the liver. Chronic infection can lead to other problems such as fibrosis of the liver, hepatocellular cancer, and end stage liver disease (Parmar, Corsi, & Cooper, 2016).
References
American Liver Foundation. (2016). http://hepc.liverfoundation.org/diagnosis/symptoms-of-hep-c/
Centers for Disease Control and Prevention. (2013). https://www.cdc.gov/hepatitis/hcv/index.htm
Centers for Disease Control and Prevention. (n.d.). https://www.cdc.gov/hepatitis/hcv/cfaq.htm
Domino, F., & Baldor, R. A. (2016). The five minute clinical consult premium 2017 (22nd ed.). Retrieved from https://www-r2library-com.chamberlainuniversity.idm.oclc.org/Resource/Title/1496339975
Laraque, F., & Varma, J. K. (2017). A public health approach to hepatitis C in an urban setting. American Journal of Public Health, 107, 922-926. https://doi.org/10.2105/AJPH.2017.303718
Laraque, F., & Varma, J. K. (2017). A public health approach to hepatitis Cin an urban setting. American Journal of Public Health, 107, 922-926. https://doi.org/10.2105/AJPH.2017.303718
Mayo Clinic. (n.d.). https://www.mayoclinic.org/diseases-conditions/hepatitis-c/symptoms-causes/syc-20354278
McCance, K. L., & Huether, S. E. (2014). Pathophysiology: The Biologic Basis for Disease in Adults and Children (7th ed.). St. Louis, MO: Elsevier.
Micromedex Solutions. (n.d.). http://www.micromedexsolutions.com.chamberlainuniversity.idm.oclc.org/micromedex2/librarian/CS/C452CE/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/5B8E4A/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=hEPATITIS%20C&UserSearchTerm=hEPATITIS%20C&SearchFilter=filterNone&navitem=searchALL#indepthpanelprint
Parmar, P., Corsi, D. J., & Cooper, C. (2016). Distribution of hepatitis C risk factors and HCV treatment outcomes among central Canadian aboriginal. Canadian Journal of Gastroenterology and Hepatology, 2016, 1-7. https://doi.org/10.1155/2016/8987976
U. S. Department of Veterans Affairs. (n.d.). https://www.hepatitis.va.gov/patient/hcv/diagnosis/labtests-hepatitisC-tests.asp
U. S. National Library of Medicine. (2018). https://medlineplus.gov/ency/article/000210.htm
Vallerand, A., Sanoski, C., & Deglin, J. (2017). Davis’s drug guide for nurses (15th ed.). Philadelphia: F. A. Davis Company. [Show Less]